A phase II study assessing Abivertinib for autoimmune disease indications, such as multiple sclerosis, systemic lupus erythematosus
Latest Information Update: 09 Apr 2021
At a glance
- Drugs Abivertinib (Primary)
- Indications Multiple sclerosis; Systemic lupus erythematosus
- Focus Adverse reactions
- 09 Apr 2021 New trial record